Latest News - DermTech

Wednesday, July 11, 2018

Dermtech’s Noninvasive Melanoma Screen Improves Care, Lowers Cost

New research shows that DermTech’s Pigmented Lesion Assay (PLA) reduces cost while improving the care of patients with primary pigmented skin lesions suggestive of melanoma. The research appears…

Read the full story

Tuesday, June 26, 2018

DermTech Initiating Study to Assess DNA Damage and Reversal

DermTech, Inc. has initiated enrollment in a clinical study to assess DNA damage induced by an excimer laser and evaluate the potential of T4 endonuclease topical DNA repair enzyme and photolyase…

Read the full story

Friday, June 15, 2018

New Data from DermTech Presented at International Investigational Dermatology Meeting

DermTech, Inc., has announced the publication of two clinical study abstracts at the 2018 International Investigational Dermatology meeting in Orlando, Fl. A real world clinical utility study, “…

Read the full story

Tuesday, May 29, 2018

DermTech: Carcinome Clinical Study Enrollment Complete

DermTech, Inc., the global leader in non-invasive molecular dermatology, announced completion of enrollment in the Carcinome™ clinical study. The goal of the Carcinome™ study is to develop…

Read the full story

Thursday, May 03, 2018

DermTech Partners with Melanoma Research Foundation to Support Miles for Melanoma

DermTech, Inc. is partnering with the Melanoma Research Foundation in support of five Miles for Melanoma Runs/Walks held throughout the US, kicking off this month during Melanoma Awareness Month.…

Read the full story

Monday, February 26, 2018

DermTech Receives State of New York Laboratory Permit

DermTech, Inc., which specializes in non-invasive molecular dermatology, has received permitting from the State of New York, Department of Public Health. The addition of a New York permit to Derm…

Read the full story

Wednesday, February 21, 2018

New DermTech Research Validates Gene Expression Against High-Risk DNA Mutations Providing Objective Information for the Diagnosis of Melanoma

DermTech, Inc. presented a late breaking abstract -- “Validation of Noninvasive Gene Expression (PLA) Against High Risk Driver Mutations (BRAF, NRAS, and TERT) in Cutaneous Melanoma” -- a…

Read the full story

Thursday, January 04, 2018

DermTech Receives Health Canada Approval to Market PLA and Non-invasive Biopsy Kit

DermTech, Inc's licensee, DermTech Canada Inc., has received approval to market DermTech’s Pigmented Lesions Assay (PLA) and non-invasive biopsy kit for the detection of melanoma in Canada. …

Read the full story

Monday, October 23, 2017

Dr. Daniel Siegel Joins DermTech's Advisory Board

DermTech, Inc., appointed Daniel M. Siegel, MD, to its Scientific Advisory Board. Dr. Siegel is a Clinical Professor of Dermatology and former Director of the Procedural Dermatology Fellowship at SUNY…

Read the full story

Tuesday, September 12, 2017

DermTech Appoints Dr. Gerald Krueger to Scientific Advisory Board

DermTech, Inc. has appointed Gerald G. Krueger, MD, to its Scientific Advisory Board. Dr. Krueger is Professor of Dermatology and Edna Benning Presidential Endowed Chair at the University of Utah in S…

Read the full story

Thursday, April 27, 2017

Non-Invasive Pigmented Lesion Assay Almost Doubles Biopsy Specificity

Dermatologists who incorporate Dermtech’s noninvasive pigmented lesion assay will biopsy fewer benign pigmented skin lesions and miss fewer melanomas, according to a new study in JAMA Derma…

Read the full story